Core Viewpoint - Addex Therapeutics reported its full-year 2024 financial results, highlighting progress in clinical development and a significant net profit from discontinued operations, primarily due to the sale of part of its business to Neurosterix [1][4][8]. Financial Performance - Total income for 2024 was CHF 410,000, a decrease of CHF 1.2 million from CHF 1.6 million in 2023 [4][11]. - Research and Development (R&D) expenses decreased to CHF 854,000 from CHF 1.2 million, while General and Administrative (G&A) expenses also decreased to CHF 2.3 million from CHF 2.7 million [4][12]. - The total operating loss increased to CHF 2.8 million in 2024 from CHF 2.2 million in 2023 [4][13]. - Net loss from continuing operations was CHF 4.9 million, an increase of CHF 2.4 million compared to CHF 2.5 million in 2023 [4][13]. - The company reported a net profit of CHF 7.1 million for the period, primarily due to a net profit from discontinued operations of CHF 12.0 million [9]. Corporate Developments - The company launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A funding to advance its preclinical portfolio [6][7]. - Indivior selected a GABAB PAM drug candidate for development in substance use disorders, while Addex selected its own GABAB PAM for chronic cough [2][6]. - Addex regained full control of its mGlu2 PAM asset, ADX71149, and repositioned dipraglurant for brain injury recovery [2][6]. Cash Position - Cash and cash equivalents decreased to CHF 3.3 million at the end of 2024 from CHF 3.9 million at the end of 2023, primarily due to cash used in operating activities [10].

Core Viewpoint - Addex Therapeutics will announce its Full-Year 2024 Financial Results on April 25, 2025, and provide a business update along with a review of its product pipeline during a teleconference and webcast [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4]. - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [4]. - The company has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders and is advancing its own GABAB PAM program for chronic cough [4]. - Addex holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs targeting schizophrenia, mood disorders, and mild neurocognitive disorders [4]. - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [4].

Core Viewpoint - Addex Therapeutics has regained all development and commercialization rights to ADX71149 (JNJ-40411813) after the termination of its partnership with Janssen Pharmaceuticals, allowing the company to explore new therapeutic indications and potential partnerships for the drug [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [2]. - The company's lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [2]. - Addex also has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders and is advancing its own GABAB PAM program for chronic cough [2]. - The company holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs for various neurological conditions [2]. Recent Developments - The termination of the partnership with Janssen Pharmaceuticals allows Addex to regain control over ADX71149, which has completed three Phase 2 studies and possesses a high-quality data package [2]. - The CEO of Addex expressed excitement about regaining control and mentioned ongoing evaluations for high-value therapeutic indications and discussions with potential partners [2].

Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company's lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [4] - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders and is advancing its own GABAB PAM program for chronic cough [4] - The company holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [4] Recent Developments - Dr. Robert Lütjens, Head of Discovery - Biology, will present a corporate update and discuss recent advances from Addex's CNS pipeline at the Swiss Equities Baader Conference [2][3] - The presentation is scheduled for January 10, 2025, at 11:40 CET in Bad Ragaz, Switzerland [3] Stock Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN" [4]

Financial Data and Key Metrics Changes - The company has made excellent progress in its GABAB positive allosteric modulator program, completing the R&D phase and delivering multiple drug candidates [6]. Business Line Data and Key Metrics Changes - A partner, Indivior, has selected a compound for development in substance use disorder and has initiated R&D enabling studies [6]. Market Data and Key Metrics Changes - No specific market data or key metrics changes were provided in the available content. Company Strategy and Development Direction and Industry Competition - The company is focused on advancing its GABAB PAM preclinical program, indicating a strategic emphasis on substance use disorder treatments [6]. Management's Comments on Operating Environment and Future Outlook - Management has expressed confidence in the progress of their R&D programs and the selection of compounds for further development [6]. Other Important Information - The financial statements and press release were made available on the company's website prior to the conference call [4]. Q&A Session Summary - No specific questions and answers from the Q&A session were provided in the available content.

Core Viewpoint - Addex Therapeutics has selected a GABAB PAM drug candidate for development in substance use disorders and is initiating IND enabling studies while also seeking partners for later clinical development stages [2][3] Financial Performance - For Q3 2024, Addex reported a net loss of CHF 1.5 million, an improvement from a net loss of CHF 2.6 million in Q3 2023, primarily due to the sale of part of its business [7] - Total operating loss for Q3 2024 was CHF 622,000, down from CHF 749,000 in Q3 2023, reflecting a decrease in R&D and G&A expenses [3][13] - Cash and cash equivalents decreased to CHF 3.3 million as of September 30, 2024, from CHF 4.7 million a year earlier, attributed to cash used in operating activities [9] Income and Expenses - Income for Q3 2024 was CHF 59,000, a significant decrease from CHF 329,000 in Q3 2023, mainly due to the completion of a research agreement with Indivior [3][10] - R&D expenses decreased to CHF 205,000 in Q3 2024 from CHF 490,000 in Q3 2023, reflecting the completion of the research agreement [3][11] - G&A expenses were stable at around CHF 1.9 million for the nine-month periods ended September 30, 2024, and 2023, with a slight decrease in Q3 2024 [12] Discontinued Operations - During the nine-month period ended September 30, 2024, net profit from discontinued operations was CHF 12.0 million, primarily due to a net gain of CHF 14.0 million from the sale of part of the business [5][6] - The net profit for the nine-month period was CHF 8.3 million, driven by the profit from discontinued operations, offset by a net loss from continuing operations of CHF 3.7 million [6] Corporate Developments - Addex is advancing an independent GABAB PAM program for chronic cough while collaborating with Indivior on substance use disorders [2][17] - The company holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs [17]

Core Viewpoint - Addex Therapeutics reported a significant decrease in net results for the third quarter of 2024, with a net loss of CHF 1.5 million compared to a net profit of CHF 12.9 million in the previous quarter, primarily due to a nonrecurring gain from a business sale in the second quarter [2][3] Financial Performance - The provisional net loss for Q3 2024 was CHF 1.5 million, a decrease of CHF 14.4 million from the net profit of CHF 12.9 million in Q2 2024 [2] - For the nine-month period ending September 30, 2024, Addex reported a net profit of CHF 8.3 million, down from CHF 9.8 million for the six-month period ending June 30, 2024 [3] - As of September 30, 2024, Addex's cash position was CHF 3.3 million [3] Upcoming Events - Addex is scheduled to release its third quarter 2024 financial results on November 22, 2024, with a teleconference and webcast for investors and analysts [4]

Core Viewpoint - Addex Therapeutics Ltd. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Outlook - The Zacks Consensus Estimate for Addex Therapeutics for the fiscal year ending December 2024 is projected at $0.49 per share, reflecting a 102.6% increase from the previous year [5]. - Over the past three months, the consensus estimate has risen by 104.2%, indicating a strong upward trend in earnings expectations [5]. Impact of Earnings Estimates - Changes in earnings estimates are strongly correlated with near-term stock price movements, primarily due to institutional investors adjusting their valuations based on these estimates [3]. - An increase in earnings estimates typically leads to higher fair value assessments by institutional investors, resulting in buying or selling activity that influences stock prices [3]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell), and has shown a strong track record of performance [4]. - Stocks rated Zacks Rank 1 have generated an average annual return of +25% since 1988, highlighting the effectiveness of the system in identifying potential investment opportunities [4]. Positioning of Addex Therapeutics - The upgrade to Zacks Rank 2 places Addex Therapeutics in the top 20% of Zacks-covered stocks, suggesting a favorable position for potential market-beating returns in the near term [7].

Financial Data and Key Metrics Changes - The company recognized $0.1 million of income in Q2 2024, down from $0.6 million in Q2 2023, primarily from research funding with Indivior [23][24] - Continuing R&D expenses remained stable at $0.3 million in Q2 2024 compared to Q2 2023 [24] - General and administrative expenses were stable at $0.7 million in Q2 2024 compared to Q2 2023 [24] - The company completed Q2 2024 with CHF3.8 million in cash, with current liabilities decreasing by CHF1.9 million compared to June 30, 2023 [24][25] Business Line Data and Key Metrics Changes - The GABAB PAM program has made significant progress, with Indivior selecting a compound for development in substance use disorders, expecting to start IND enabling studies in H1 2025 [7][9] - The independent GABAB PAM program for chronic cough is expected to start IND enabling studies in 2025, pending financing [9][18] Market Data and Key Metrics Changes - The company launched Neurosterix with a Series A financing of $63 million, securing a 20% equity interest in the new entity [6][22] - The Neurosterix transaction is expected to alleviate financing pressures on Addex, allowing for the advancement of its preclinical portfolio [22][30] Company Strategy and Development Direction - The company aims to advance its GABAB PAM program for chronic cough and is exploring various clinical indications, including refractory chronic cough and COPD [29][30] - The strategic spin-out of Neurosterix is seen as a transformative move, strengthening the balance sheet and securing financing for preclinical development [22][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of dipraglurant for brain injury recovery, highlighting the large unmet medical need in post-stroke rehabilitation [10][11] - The company is focused on achieving better efficacy and tolerability compared to existing treatments in the chronic cough space [32][34] Other Important Information - The company has divested its allosteric modulation technology platform but retains a service agreement with Neurosterix to access necessary skills [22] - The company is on track to complete IND-enabling studies for Neurosterix compounds by mid-next year, with plans to file INDs for Phase 1 trials in the second half of 2025 [40] Q&A Session Summary Question: What specific clinical indications are being considered for the chronic cough program? - The company is considering refractory and unexplained chronic cough, as well as COPD or IPF-related chronic cough [29] Question: Are MED and ED50 used interchangeably? - No, MED refers to minimum effective dose, while ED50 is the effective dose that achieves 50% of the effect [30] Question: What comparator molecules will be used in the chronic cough program? - The company will consider baclofen and other GABAB PAMs, aiming for similar or better efficacy with improved tolerability [32] Question: Will Camlipixant be a competitor? - Yes, the company expects Camlipixant to be the standard-of-care by the time they reach later-stage development [33] Question: What are the prospects for the Neurosterix portfolio compounds? - The company anticipates completing IND-enabling studies in the middle of next year and filing INDs for Phase 1 trials in the second half of 2025 [40]

Core Insights - Addex Therapeutics reported a significant increase in provisional half-year and second quarter net results for 2024, primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024 [1][2] Financial Performance - The provisional net gain for the six-month period ended June 30, 2024, amounted to CHF 9.8 million, compared to a net loss of CHF 5.1 million for the same period in 2023, reflecting an increase of CHF 14.9 million [2] - The increase is attributed to gross proceeds of CHF 5.0 million received in cash from the business sale and a fair value of CHF 9.4 million for a 20% equity interest in Neurosterix US holdings LLC [2] - As of June 30, 2024, the cash position of the Group was CHF 3.8 million [2] Upcoming Events - The company plans to issue its Half-Year 2024 Financial Results on September 30, 2024, with a teleconference and webcast for investors, analysts, and media scheduled for the same day at 16:00 CEST [3] Company Overview - Addex Therapeutics is focused on developing novel small molecule allosteric modulators for neurological disorders, with its lead drug candidate, dipraglurant, under evaluation for brain injury recovery [5] - The company has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, with IND enabling studies expected to start in H1 2025 [5] - Addex also holds a 20% equity interest in Neurosterix LLC, which is advancing various allosteric modulator programs [5]